Incyte's atopical dermatitis cream delayed

The US FDA needs more time for its review of a new cream for the treatment of atopical dermatitis from the company Incyte. This delay could benefit Leo Pharma.

Photo: Andrew Kelly/REUTERS / X02844

It will be another three months before the US Food and Drug Administration (FDA) is ready to give its verdict on the drug ruxolitinib from Incyte. The review period for the drug ruxolitinib has been extended until Sept. 21, according a company press release.

Ruxolitinib is administered as a topical treatment for atopical dermatitis, and it is in the class of drugs known as JAK-inhibitors.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs